Roche stock holds its ground as 2025 earnings and 2026 guidance frame the trade
Published on 08/09/2026 at 14:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding (CH0012032048) is being read through its latest reported numbers: 2025 sales of CHF 60.5 billion, core EPS of CHF 19.84, and a proposed dividend of CHF 9.70 per share all frame the stock’s current setup. The company also said in its 2025 reporting that 2026 sales are expected to grow in the low to mid single-digit range at constant exchange rates, giving the market a dated reference point for the next leg of performance.
2025 sales set the base
Roche’s 2025 sales total of CHF 60.5 billion provides the main operating anchor, while core EPS of CHF 19.84 shows how much earnings power the group still generated in the year. The dividend proposal of CHF 9.70 per share adds a second shareholder-return metric that investors can compare with prior years and with the company’s cash generation profile.
The most important comparison is the 2026 outlook against 2025: sales are guided to rise in the low to mid single-digit range at constant exchange rates, which signals moderate top-line growth rather than a sharp acceleration. That guidance matters more than broad sector language because it ties the next year directly to the reported CHF 60.5 billion base.
Guidance stays measured
For Roche stock, the immediate question is whether that guidance band is enough to support a rerating after a year in which the business still delivered CHF 19.84 in core EPS. The combination of a CHF 9.70 dividend proposal and a low to mid single-digit sales outlook points to a company leaning on stability, not on a dramatic reset.
That is also where the current market lens sits: investors usually test whether the earnings base can hold while growth remains in a modest range. On that score, the 2025 report supplies the core facts, and the 2026 guidance supplies the comparison that keeps the discussion current.
Core drugs still matter
Roche’s product mix remains central to the investment case, especially the pharmaceuticals portfolio that carries the group’s largest revenue contribution. The company’s reported 2025 sales and 2026 outlook show that product execution, not abstract sector momentum, is what will drive the next update to Roche Holding stock.
That is why the market continues to focus on whether the established portfolio can keep revenue close to the CHF 60.5 billion level while the pipeline advances toward the next report cycle. The numbers already on record leave little room for vagueness: sales, core EPS, and dividend all need to keep doing the heavy lifting.
Roche pharmaceuticals
The pharmaceuticals division is the clearest representative business line for Roche because it links product launches, patent cycles, and revenue durability. In the latest reported year, that wider group generated CHF 60.5 billion in sales, and the next-year guidance still depends on that core franchise carrying the bulk of the load.
Stock level and as-of view
As a market value reference, Roche stock traded at CHF 264.80 on SIX as of 09 August 2026, giving the share price a dated anchor against the 2025 earnings base and the 2026 guidance range. The stock therefore sits between a mature earnings profile and a still-positive growth outlook, which is the mix investors will keep comparing with the next company update.
Roche Holding key facts
- Company: Roche Holding AG
- ISIN: CH0012032048
- Ticker: SIX: RO
- Trading venue: SIX Swiss Exchange
- Price (as of 09 August 2026, 12:00 UTC): CHF 264.80
- Market capitalization: CHF 212.4 billion (as of 09 August 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Swiss Market Index
